Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2011. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is limited to reporting a specific transaction event rather than presenting comprehensive financial statements.
Material Changes
The filing reports a re-valuation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary share ADRs on August 4, 2011, at a price of $42.20 per ADR. No other material changes to the company's financial position are disclosed in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies. It strictly details the notification of the ADR allocation increase in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Key Facts for Investor Verification
- Transaction Date: August 4, 2011 (Notification date: August 5, 2011).
- Transaction Type: Increase in notional allocation of Ordinary share ADRs within the US Retirement Savings Plan.
- Price per ADR: $42.20.
- Individuals Affected: Dr M M Slaoui (9 ADRs), Dr K Slaoui (8 ADRs), Mr W C Louv (16 ADRs), Dr D Pulman (29 ADRs), Mr E J Gray (22 ADRs), and Mrs D P Connelly (1 ADR).
- Regulatory Basis: Filed pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934.